

B. What are the equipment parameters that are necessary to achieve desired outcomes (e.g. flow capabilities, settings, etc.)?

C. What are the parameters of prescribed patient usage (e.g. frequency of use, duration of use throughout the day, other)?

D. In each of the above populations, what are the parameters of patient compliance with the prescribed usage of the equipment?

IV. What respiratory services, other than the technical support of the use of the prescribed equipment, are being provided to the above patients in the home (e.g. patient education, ongoing smoking cessation, respiratory therapist led home care)?

V. What are the professional guidelines and statements which address KQ 1 to KQ 4?

#### **PICOTS (Populations, Interventions, Comparators, Outcomes, Timing, Settings)**

##### *Population(s)*

- I. Adults 18 years and older with chronic respiratory failure due to:
  - A. Neuromuscular diseases
  - B. Thoracic restrictive diseases (including thoracic cage abnormalities and morbid obesity)
  - C. Chronic obstructive pulmonary disease
  - D. Other lung diseases (cystic fibrosis, bronchiectasis)

##### *Interventions*

- I. Home mechanical ventilators (FDA-approved only) with or without pertinent ancillary in-home services (e.g. respiratory therapy in the home; pharmacy reconciliation; smoking cessation, etc.)
- II. BPAP respiratory assist devices (FDA-approved only) w/or w/o pertinent ancillary in-home services
- III. CPAP respiratory assist devices (FDA-approved only) w/or w/o pertinent ancillary in-home services

##### *Comparators*

- I. Usual care (i.e. no mechanical ventilation/BPAP/CPAP)
- II. Different type of noninvasive mechanical ventilation
- III. Different modes of same equipment
- IV. Other noninvasive ventilation

(Studies without a comparator treatment that evaluate the effect of a patient characteristic, laboratory criteria, ventilator parameter, or respiratory services on outcomes of interest will be included)

##### *Outcomes*

##### Patient-Centered Outcomes

- I. Mortality

II. Hospitalization

III. Admission/readmission to intensive care unit (ICU)

IV. Need for intubation

V. Outpatient visits

VI. Emergency room visits

VII. Disease exacerbations

VIII. Quality of life (QoL)

IX. Activities of daily living (ADL)

X. Dyspnea

XI. Sleep quality

XII. Exercise tolerance

XIII. Adverse events

##### Timing

- I. At least 1 month of treatment

##### Setting

- I. Home
- II. Assisted living residence

##### Publication Time

- I. From 1995

##### Subgroup Analysis

- I. Type of diseases
  - A. Neuromuscular diseases
  - B. Thoracic restrictive diseases
    - i. Thoracic cage abnormalities
    - ii. Morbid obesity
  - C. COPD
  - D. Other lung diseases (cystic fibrosis, bronchiectasis)
- II. Length of treatment (1 month, 3 months, 6 months and longer)

**Karen J. Migdail,**  
*Chief of Staff.*

[FR Doc. 2018-03927 Filed 2-26-18; 8:45 am]

**BILLING CODE 4160-90-P**

#### **DEPARTMENT OF HEALTH AND HUMAN SERVICES**

##### **Agency for Healthcare Research and Quality**

##### **Meeting of the National Advisory Council for Healthcare Research and Quality**

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Notice of public meeting.

**SUMMARY:** This notice announces a meeting of the National Advisory Council for Healthcare Research and Quality.

**DATES:** The meeting will be held on Friday, March 16, 2018, from 11:00 a.m. to 1:00 p.m. (EST).

**ADDRESSES:** The meeting will be held virtually (via WebEx).

**FOR FURTHER INFORMATION CONTACT:** Jaime Zimmerman, Designated Management Official, at the Agency for Healthcare Research and Quality, 5600 Fishers Lane, Mail Stop 06E37A,

Rockville, Maryland, 20857, (301) 427-1456. For press-related information, please contact Alison Hunt at (301) 427-1244 or at [Alison.Hunt@ahrq.hhs.gov](mailto:Alison.Hunt@ahrq.hhs.gov). Closed captioning will be provided during the WebEx. If another accommodation for a disability is needed, please contact the Food and Drug Administration (FDA) Office of Equal Employment Opportunity and Diversity Management on (301) 827-4840, no later than Friday, March 9, 2018.

#### **SUPPLEMENTARY INFORMATION:**

##### **I. Purpose**

The National Advisory Council for Healthcare Research and Quality is authorized by Section 941 of the Public Health Service Act, 42 U.S.C. 299c. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director of AHRQ on matters related to AHRQ's conduct of its mission including providing guidance on (A) priorities for health care research, (B) the field of health care research including training needs and information dissemination on health care quality and (C) the role of the Agency in light of private sector activity and opportunities for public private partnerships. The Council is composed of members of the public, appointed by the Secretary, and Federal ex-officio members specified in the authorizing legislation.

##### **II. Agenda**

On Friday, March 16, 2018, the Council meeting will convene via WebEx at 11:00 a.m. (EST), with the call to order by the Council Chair and approval of previous Council summary notes. The agenda will include an update by the AHRQ Director and an update on the Healthcare Cost and Utilization Project (HCUP) new release of county level statistics on hospital stays for alcohol, opioids, and other drugs. The meeting is open to the public. For information regarding how to access the WebEx as well as other meeting details, please go to <https://www.ahrq.gov/news/events/nac/>.

**Karen J. Migdail,**  
*Chief of Staff.*

[FR Doc. 2018-03926 Filed 2-26-18; 8:45 am]

**BILLING CODE 4160-90-P**